PreLIM Project
PreLIM focuses on the development of novel preclinical models of leukemias and lymphomas in the development of novel targeted and immune therapies, and exploration of microenvironmental factors critical to disease development and emergence of resistant clones. The PreLIM group has identified that stabilization of β-catenin upon B-cell receptor signaling promotes NF-kB target genes transcription in mantle cell lymphoma.
Furthermore, the group has identified novel small molecule therapeutic targets in mantle cell lymphoma and initiated collaboration with the Moffitt Cancer Center in the development of several novel cell-based immunotherapeutics. Sahba Shafiee successfully defended her thesis on “Translational Development of Preclinical Models and Therapies in Myelodysplastic Syndromes (MDS).”
precoslab.com 